Translating genomics for precision cancer medicine

Annual Review of Genomics and Human Genetics

Volumn 15, Issue , 2014, Pages 395-415

  Roychowdhury, Sameek ^a   Chinnaiyan, Arul M ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

cancer; precision oncology; resistance mechanisms

Indexed keywords

TUMOR MARKER;

ACCURACY; BREAST CANCER; CANCER GENETICS; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); GENE MUTATION; GENE REARRANGEMENT; GENOMICS; HUMAN; LUNG CANCER; MELANOMA; MOLECULAR DIAGNOSTICS; NONHUMAN; PROSTATE CANCER; REVIEW; SEQUENCE ANALYSIS; TAXONOMY; TUMOR BIOPSY; DNA SEQUENCE; GENETICS; HUMAN GENOME; MEDICAL RESEARCH; MUTATION; NEOPLASMS; PATHOLOGY; PROCEDURES;

BIOMEDICAL RESEARCH; GENOME, HUMAN; GENOMICS; HUMANS; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84906886385     PISSN: 15278204     EISSN: 1545293X     Source Type: Book Series    
DOI: 10.1146/annurev-genom-090413-025552     Document Type: Review

References (122)

1. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, et al. 2014. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59:1427-34
2. Awad MM, Katayama R, McTigue M, Liu W, Deng YL, et al. 2013. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368:2395-401
3. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, et al. 2004. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3:772-75
4. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, et al. 2012. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405-9
5. Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, et al. 2013. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J. Mol. Diagn. 15:171-76
6. Besa EC. 2014. Chronic myelogenous leukemia. Medscape, updated Mar. 24. http://emedicine.medscape. com/article/199425-overview#aw2aab6b2b3
7. Bloomfield CD, Lindquist LL, Arthur D, McKenna RW, LeBien TW, et al. 1981. Chromosomal abnormalities in acute lymphoblastic leukemia. Cancer Res. 41:4838-43
8. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, et al. 2012. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. Drug Discov. 11:873-86
9. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, et al. 2013. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3:224-37
10. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, et al. 2011. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19:664-78
11. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, et al. 2010. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363:1727-33
12. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, et al. 2007. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-44
13. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, et al. 2004. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J. Neuropathol. Exp. Neurol. 63:1236-42
14. Chang BY, Zapatka M, Barrientos JC, Li D, Steggerda S, et al. 2013. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). J. Clin. Oncol. 31(Suppl.):7014 (Abstr.)
15. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-16
16. Chen Y, Takita J, Choi YL, Kato M, Ohira M, et al. 2008. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971-74
17. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, et al. 2010. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363:1734-39
18. Clin. Lung Cancer Genome Proj., Netw. Genomic Med. 2013. A genomics-based classification of human lung tumors. Sci. Transl. Med. 5:209ra153
19. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, et al. 2012. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2:227-35
20. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, et al. 2002. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 8:3034-38
21. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-54
22. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, et al. 2013. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368:1199-209
23. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, et al. 2012. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-40
24. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. 2012. BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366:2038-40
25. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506-10
26. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, et al. 2012. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18:1472-82
27. Downing JR, Wilson RK, Zhang J, Mardis ER, Pui CH, et al. 2012. The Pediatric Cancer Genome Project. Nat. Genet. 44:619-22
28. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-37
29. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-66
30. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, et al. 2013. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45:478-86
31. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, et al. 2011. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 6:e20351
32. El-Osta H, Hong D, Wheler J, Fu S, Naing A, et al. 2011. Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center experience. Oncologist 16:1292-98
33. Ellis MJ, Perou CM. 2013. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 3:27-34
34. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, et al. 2011. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208:1389-401
35. Flaherty KT, McArthur G. 2010. BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 116:4902-13
36. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363:809-19
37. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, et al. 2012. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367:107-14
38. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, et al. 2013. Developmentandvalidation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31:1023-31
39. Frei E III, Karon M, Levin RH, Freireich EJ, Taylor RJ, et al. 1965. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26:642-56
40. Gainor JF, Shaw AT. 2013. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J. Clin. Oncol. 31:3987-96
41. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, et al. 2012. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat. Biotechnol. 30:1033-36
42. Garraway LA, Lander ES. 2013. Lessons from the cancer genome. Cell 153:17-37
43. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883-92
44. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, et al. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-43
45. Green ED, Guyer MS, Manolio TA, Peterson JL. 2011. Charting a course for genomic medicine from base pairs to bedside. Nature 470:204-13
46. Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL. 2010. The occurrence of rare cancers in U.S. adults, 1995-2004. Public Health Rep. 125:28-43
47. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, et al. 2011. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1:78-89
48. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
49. Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, et al. 2012. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2:948-59
50. Ho DD, Bieniasz PD. 2008. HIV-1 at 25. Cell 133:561-65
51. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, et al. 2012. A landscape of driver mutations in melanoma. Cell 150:251-63
52. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, et al. 2012. Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221
53. Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, et al. 2013. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3:1364-77
54. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, et al. 2013. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23:603-17
55. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, et al. 2013. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 3:1020-29
56. Kaiser J. 2013. Rare cancer successes spawn "exceptional" research efforts. Science 340:263
57. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502:333-39
58. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, et al. 2012. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4:120ra17
59. Konstantinopoulos PA, Papavassiliou AG. 2011. Seeing the future of cancer-associated transcription factor drug targets. JAMA 305:2349-50
60. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, et al. 2012. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2:591-97
61. Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, et al. 2012. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119:1963-71
62. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363:1693-703
63. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214-18
64. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, et al. 2012. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4:162ra54
65. Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, et al. 2013. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 73:5195-205
66. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, et al. 2012. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18:382-84
67. Lito P, Rosen N, Solit DB. 2013. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19:1401-9
68. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-39
69. Malaney P, Nicosia SV, Davé V. 2014. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 344:1-12
70. Mardis ER. 2011. A decade's perspective on DNA sequencing technology. Nature 470:198-203
71. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. 2013. Building a personalized medicine infrastructure at a major cancer center. J. Clin. Oncol. 31:1849-57
72. Meyerson M, Gabriel S, Getz G. 2010. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11:685-96
73. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, et al. 2013. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108-12
74. Nakano H, Yamamoto F, Neville C, Evans D, Mizuno T, Perucho M. 1984. Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes. Proc. Natl. Acad. Sci. USA 81:71-75
75. Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. 2011. The APL paradigm and the "co-clinical trial" project. Cancer Discov. 1:108-16
76. Natl. Res. Counc. Comm. Framew. Dev. New Taxon. Dis. 2011. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: Natl. Acad. Press
77. Nowell PC, Hungerford D. 1960. A minute chromosome in human chronic granulocytic leukemia. Science 132:1497 (Abstr.)
78. Ocana A, Amir E, Vera-Badillo F, Seruga B, Tannock IF. 2013. Phase III trials of targeted anticancer therapies: redesigning the concept. Clin. Cancer Res. 19:4931-40
79. Olson EM, Lin NU, Krop IE, Winer EP. 2011. The ethical use of mandatory research biopsies. Nat. Rev. Clin. Oncol. 8:620-25
80. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500
81. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, et al. 2011. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 29:2046-51
82. Pao W, Girard N. 2011. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175-80
83. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-91
84. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. 2000. Molecular portraits of human breast tumours. Nature 406:747-52
85. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, et al. 2012. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100-3
86. Pritchard CC, Salipante SJ, Koehler K, Smith C, Scroggins S, et al. 2014. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J. Mol. Diagn. 16:56-67
87. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101-5
88. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, et al. 2006. FGFR1 emerges asapotential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 12:6652-62
89. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, et al. 2012. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22:153-66
90. Robinson DR, Kalyana-Sundaram S, Wu YM, Shanker S, Cao X, et al. 2011. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 17:1646-51
91. Robinson DR, Wu Y-M, Vats P, Su F, Lonigro RJ, et al. 2013. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45:1446-51
92. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, et al. 2013. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAF V600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin. Cancer Res. 19:5749-57
93. Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-93
94. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, et al. 2000. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 6:1038-45
95. Ryan CJ, Tindall DJ. 2011. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J. Clin. Oncol. 29:3651-58
96. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, Barbacid M. 1984. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223:661-64
97. Sato T, Clevers H. 2013. Growing self-organizing mini-guts froma single intestinal stem cell: mechanism and applications. Science 340:1190-94
98. Sawyers CL. 2008. The cancer biomarker problem. Nature 452:548-52
99. Sharma MR, Schilsky RL. 2011. Role of randomized phase III trials in an era of effective targeted therapies. Nat. Rev. Clin. Oncol. 9:208-14
100. V600EBRAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3:724
101. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, et al. 2013. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J. Mol. Diagn. 15:607-22
102. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-66
103. Sordella R, Bell DW, Haber DA, Settleman J. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-67
104. Sotiriou C, Piccart MJ. 2007. Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? Nat. Rev. Cancer 7:545-53
105. Sparano JA, Paik S. 2008. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26:721-28
106. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400-4
107. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, et al. 2012. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4
108. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, et al. 2012. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18:378-81
109. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, et al. 2013. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci. Rep. 3:2650
110. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, et al. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332:1393-98
111. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, et al. 2012. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9:338-50
112. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, et al. 2011. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364:2305-15
113. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, et al. 2011. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 3:94ra72
114. Toy W, Shen Y, Won H, Green B, Sakr RA, et al. 2013. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45:1439-45
115. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, et al. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9:401-6
116. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. 2013. Cancer genome landscapes. Science 339:1546-58
117. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, et al. 2011. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29:3085-96
118. Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, et al. 2011. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov. 1:35-43
119. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. 2013. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45:1113-20
120. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, et al. 2013. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3:636-47
121. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, et al. 2011. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 43:932-39
122. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, et al. 2012. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:157-63